{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:01:31Z","timestamp":1784127691591,"version":"3.55.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:00:00Z","timestamp":1768089600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biliary tract cancers (BTCs), including gallbladder cancer (GBC) and cholangiocarcinoma (CCA), are rare but aggressive malignancies with distinct molecular landscapes and poor prognoses. Genomic profiling has revealed significant molecular alterations, but the genomic landscape of BTC in the Indian population remains underexplored. This study aims to comprehensively characterize the mutation landscape of BTC in the Indian population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 154 BTC cases, including 69 CCA and 85 GBC, were retrospectively analyzed using data collected from various targeted sequencing panels. Somatic mutations, copy number variations (CNVs), and gene fusions in key oncogenic and tumor suppressor genes were identified from these panel reports. Downstream analyses were performed to derive key biological insights, including pathway enrichment and mutual exclusivity and co-occurrence analyses of genomic alterations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TP53 was the most frequently mutated gene (53%), followed by KRAS (18%), ARID1A (9%), IDH1 (7%), and PIK3CA (7%). Recurrent amplifications were observed in MYC (12%) and ERBB2 (9%). Pathway enrichment analysis revealed significant dysregulation in the PI3K-AKT-mTOR, Notch, and Wnt\/\u03b2-catenin signaling pathways. Notably, IDH1 mutations were primarily observed in CCA, while STK11 mutations were exclusive to GBC, highlighting distinct molecular characteristics between the two subtypes. PD-L1-negative tumors exhibited distinct genomic alterations, notably SMAD4 mutations, which were associated with reduced PD-L1 expression. This loss of SMAD4, involved in TGF-\u03b2 signaling, could impair immune response regulation and facilitate immune evasion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides a comprehensive molecular profiling of BTCs in the Indian population, revealing key genomic alterations, subtype-specific differences, and associations with immune features. The findings underscore the importance of molecular profiling in guiding personalized treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf430","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:43:43Z","timestamp":1767876223000},"source":"Crossref","is-referenced-by-count":3,"title":["Actionable genomic landscape of biliary tract cancer in the Indian population"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4989-9117","authenticated-orcid":false,"given":"Sewanti","family":"Limaye","sequence":"first","affiliation":[{"name":"Department of Medical and Precision Oncology, Sir H N Reliance Foundation Hospital and Research Centre , Mumbai 422010,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Shreenivas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Centre , Duarte, CA 422010,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshana","family":"Patil","sequence":"additional","affiliation":[{"name":"Datar Cancer Genetics , Nashik, Maharashtra 422010,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumil","family":"Vyas","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Sir H N Reliance Foundation Hospital and Research Centre , Mumbai 51122,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene A","family":"George","sequence":"additional","affiliation":[{"name":"Manipal Academy of Higher Education (MAHE) , Manipal, Karnataka 576104,","place":["India"]},{"name":"Institute of Bioinformatics, International Technology Park , Bangalore, Karnataka 560066,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janani","family":"Sambath","sequence":"additional","affiliation":[{"name":"Manipal Academy of Higher Education (MAHE) , Manipal, Karnataka 576104,","place":["India"]},{"name":"Institute of Bioinformatics, International Technology Park , Bangalore, Karnataka 560066,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shambhavi","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Medical and Precision Oncology, Sir H N Reliance Foundation Hospital and Research Centre , Mumbai 422010,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Madre","sequence":"additional","affiliation":[{"name":"Department of Medical and Precision Oncology, Sir H N Reliance Foundation Hospital and Research Centre , Mumbai 422010,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Parab","sequence":"additional","affiliation":[{"name":"Department of Medical and Precision Oncology, Sir H N Reliance Foundation Hospital and Research Centre , Mumbai 422010,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritam","family":"Kataria","sequence":"additional","affiliation":[{"name":"Department of Medical and Precision Oncology, Sir H N Reliance Foundation Hospital and Research Centre , Mumbai 422010,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshit","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medical and Precision Oncology, Sir H N Reliance Foundation Hospital and Research Centre , Mumbai 422010,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niyati","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medical and Precision Oncology, Sir H N Reliance Foundation Hospital and Research Centre , Mumbai 422010,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheenah","family":"Dawood","sequence":"additional","affiliation":[{"name":"Mediclinic Parkview Hospital , Dubai 51122,","place":["United Arab Emirates (UAE)"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitesh","family":"Rohatgi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fortis Memorial Research Institute , Gurugram 122002,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruturaj","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Department of Medical and Precision Oncology, Sir H N Reliance Foundation Hospital and Research Centre , Mumbai 422010,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakriti","family":"Datta","sequence":"additional","affiliation":[{"name":"Datar Cancer Genetics , Nashik, Maharashtra 422010,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humaid Al","family":"Shamsi","sequence":"additional","affiliation":[{"name":"Founder and Director of the Medical Oncology Service at Burjeel Medical City , 9054,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gaya","sequence":"additional","affiliation":[{"name":"Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, University of London , Great Maze Pond SE1 9RT, London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok Kumar","family":"Vaid","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Medanta the Medicity , Gurugram 122001,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shriniwas","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Sahyadri Super Speciality Hospital , Pune 411004,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil","family":"Rajappa","sequence":"additional","affiliation":[{"name":"Basavatarakam Indo-American Cancer Hospital and Research Institute, Banjara Hills , Hyderabad 13353,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0027-7977","authenticated-orcid":false,"given":"Damian","family":"Rieke","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin 13353,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kumar","sequence":"additional","affiliation":[{"name":"Datar Cancer Genetics , Nashik, Maharashtra 422010,","place":["India"]},{"name":"Koita Centre for Digital Health\u2014Indian Institute of Technology Bombay , Mumbai 400076,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Datar","sequence":"additional","affiliation":[{"name":"Datar Cancer Genetics , Nashik, Maharashtra 422010,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9158-0941","authenticated-orcid":false,"given":"Milind","family":"Javle","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, MD Anderson Centre in Houston , TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"2026021302362983000_oyaf430-B1","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/j.annonc.2024.05.296","article-title":"290P global epidemiology trends in biliary tract cancer: a targeted literature review","volume":"35","author":"Bridgewater","year":"2024","journal-title":"Ann Oncol"},{"key":"2026021302362983000_oyaf430-B2","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2147\/CMAR.S157092","article-title":"Biliary tract cancers: current knowledge, clinical candidates and future challenges","volume":"11","author":"Tariq","year":"2019","journal-title":"Cancer Manag Res"},{"key":"2026021302362983000_oyaf430-B3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"2026021302362983000_oyaf430-B4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13023-025-03652-0","article-title":"Epidemiology of gall bladder cancer and its prevalence worldwide: a meta-analysis","volume":"20","author":"Afzal","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"2026021302362983000_oyaf430-B5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21037\/cco.2019.08.03","article-title":"Epidemiology of gallbladder cancer in India","volume":"8","author":"Dutta","year":"2019","journal-title":"Chin Clin Oncol"},{"key":"2026021302362983000_oyaf430-B6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/sujhs.sujhs_12_24","article-title":"Epidemiology of gallbladder cancer in India 2018\u20132023","volume":"10","author":"Bhagat","year":"2024","journal-title":"Santosh Univ J Health Sci"},{"key":"2026021302362983000_oyaf430-B7","doi-asserted-by":"crossref","first-page":"107064","DOI":"10.1016\/j.ejso.2023.107064","article-title":"Epidemiology of cholangiocarcinoma","volume":"51","author":"Qurashi","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"2026021302362983000_oyaf430-B8","doi-asserted-by":"crossref","first-page":"652","DOI":"10.21037\/jgo.2018.08.18","article-title":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","volume":"10","author":"Weinberg","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"2026021302362983000_oyaf430-B9","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1038\/s41467-020-17880-4","article-title":"Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate","volume":"11","author":"Pandey","year":"2020","journal-title":"Nat Commun"},{"key":"2026021302362983000_oyaf430-B10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1055\/s-0040-1721180","article-title":"Genomic landscape and targeted treatment of gallbladder cancer: results of a first ongoing prospective study","volume":"9","author":"Patel","year":"2020","journal-title":"South Asian J Cancer"},{"key":"2026021302362983000_oyaf430-B11","doi-asserted-by":"crossref","first-page":"114046","DOI":"10.1016\/j.ejca.2024.114046","article-title":"Unresectable biliary tract cancer: current and future systemic therapy","volume":"203","author":"Zhang","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026021302362983000_oyaf430-B12","doi-asserted-by":"crossref","first-page":"100092","DOI":"10.1016\/j.esmogo.2024.100092","article-title":"New perspectives in biliary tract cancers","volume":"5","author":"Goetze","year":"2024","journal-title":"ESMO Gastrointest Oncol"},{"key":"2026021302362983000_oyaf430-B13","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/jcb.25592","article-title":"TP53 mutations in head and neck squamous cell carcinoma and their impact on disease progression and treatment response","volume":"117","author":"Zhou","year":"2016","journal-title":"J Cell Biochem"},{"key":"2026021302362983000_oyaf430-B14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2147\/CMAR.S157156","article-title":"Biliary tract cancer: current challenges and future prospects","volume":"11","author":"Ghidini","year":"2019","journal-title":"Cancer Manag Res"},{"key":"2026021302362983000_oyaf430-B15","doi-asserted-by":"crossref","first-page":"e2100510","DOI":"10.1200\/PO.21.00510","article-title":"Clinical, genomic, and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures","volume":"6","author":"Mody","year":"2022","journal-title":"JCO Precis Oncol."},{"key":"2026021302362983000_oyaf430-B16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12885-021-07792-x","article-title":"Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma","volume":"21","author":"Xu","year":"2021","journal-title":"BMC Cancer"},{"key":"2026021302362983000_oyaf430-B17","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/jso.28081","article-title":"Genomic profiling of biliary tract cancers: comprehensive assessment of anatomic and geographic heterogeneity, co-alterations and outcomes","volume":"131","author":"Tsilimigras","year":"2025","journal-title":"J Surg Oncol"},{"key":"2026021302362983000_oyaf430-B18","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1200\/JCO.2021.39.15_suppl.4106","article-title":"Clinical outcomes analysis of TP53-mutated advanced and metastatic biliary tract cancers","volume":"39","author":"Lee","year":"2021","journal-title":"JCO"},{"key":"2026021302362983000_oyaf430-B19","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ejso.2022.03.005","article-title":"Meta-analysis on prognostic value of KRAS mutation in resected mass-forming cholangiocarcinoma","volume":"48","author":"Procopio","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"2026021302362983000_oyaf430-B20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4137\/JCM.S40549","article-title":"KRAS mutation as a potential prognostic biomarker of biliary tract cancers","volume":"7","author":"Yokoyama","year":"2016","journal-title":"Jpn Clin Med"},{"key":"2026021302362983000_oyaf430-B21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamasurg.2021.5679","article-title":"Association of KRAS variant subtypes with survival and recurrence in patients with surgically treated intrahepatic cholangiocarcinoma","volume":"157","author":"Zhou","year":"2022","journal-title":"JAMA Surg"},{"key":"2026021302362983000_oyaf430-B22","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.2024.42.3_suppl.492","article-title":"Characterizing outcomes of ERBB2-amplified biliary tract cancer","volume":"42","author":"Fox","year":"2024","journal-title":"JCO"},{"key":"2026021302362983000_oyaf430-B23","doi-asserted-by":"crossref","first-page":"846744","DOI":"10.3389\/fonc.2022.846744","article-title":"FGF19 is coamplified with CCND1 to promote proliferation in lung squamous cell carcinoma and their combined inhibition shows improved efficacy","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"2026021302362983000_oyaf430-B24","doi-asserted-by":"crossref","first-page":"e16044","DOI":"10.1200\/JCO.2023.41.16_suppl.e16044","article-title":"Co-occurrence of mutations and related signal pathway analysis of CCND1 amplification in esophageal squamous cell cancer","volume":"41","author":"Pang","year":"2023","journal-title":"JCO"},{"key":"2026021302362983000_oyaf430-B25","doi-asserted-by":"crossref","first-page":"918317","DOI":"10.3389\/fphar.2022.918317","article-title":"LY2874455 and abemaciclib reverse FGF3\/4\/19\/CCND1 amplification mediated gefitinib resistance in NSCLC","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026021302362983000_oyaf430-B26","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1111\/jcmm.17828","article-title":"Contribution of PGAP3 co-amplified and co-overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer","volume":"27","author":"Wang","year":"2023","journal-title":"J Cell Mol Med"},{"key":"2026021302362983000_oyaf430-B27","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.humpath.2013.11.001","article-title":"Molecular characterization of gallbladder cancer using somatic mutation profiling","volume":"45","author":"Javle","year":"2014","journal-title":"Hum Pathol"},{"key":"2026021302362983000_oyaf430-B28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejca.2021.01.050","article-title":"STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications","volume":"148","author":"Krishnamurthy","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026021302362983000_oyaf430-B29","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.21037\/jtd-21-1377","article-title":"Clinical outcomes and immune phenotypes associated with STK11 co-occurring mutations in non-small cell lung cancer","volume":"14","author":"Malhotra","year":"2022","journal-title":"J Thorac Dis"},{"key":"2026021302362983000_oyaf430-B30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fendo.2020.00189","article-title":"Mutation of isocitrate dehydrogenase 1 in cholangiocarcinoma impairs tumor progression by inhibiting isocitrate metabolism","volume":"11","author":"Su","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026021302362983000_oyaf430-B31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/curroncol32010044","article-title":"IDH mutant cholangiocarcinoma: pathogenesis, management, and future therapies","volume":"32","author":"Bray","year":"2025","journal-title":"Curr Oncol"},{"key":"2026021302362983000_oyaf430-B32","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026021302362983000_oyaf430-B33","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026021302362983000_oyaf430-B34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.32074\/1591-951X-859","article-title":"FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice","volume":"115","author":"Angerilli","year":"2023","journal-title":"Pathologica"},{"key":"2026021302362983000_oyaf430-B35","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41416-022-01908-1","article-title":"Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing","volume":"127","author":"Neumann","year":"2022","journal-title":"Br J Cancer"},{"key":"2026021302362983000_oyaf430-B36","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"2026021302362983000_oyaf430-B37","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"2026021302362983000_oyaf430-B38","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1200\/JCO.2024.42.16_suppl.4093","article-title":"Three-year follow-up data from KEYNOTE-966: pembrolizumab (pembro) plus gemcitabine and cisplatin (gem\/cis) compared with gem\/cis alone for patients (pts) with advanced biliary tract cancer (BTC)","volume":"42","author":"Finn","year":"2024","journal-title":"JCO"},{"key":"2026021302362983000_oyaf430-B39","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.3390\/cancers15133312","article-title":"Immunotherapy in biliary tract cancers: current standard-of-care and emerging strategies","volume":"15","author":"Lo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026021302362983000_oyaf430-B40","doi-asserted-by":"crossref","first-page":"806963","DOI":"10.3389\/fonc.2022.806963","article-title":"Loss of SMAD4 is associated with poor tumor immunogenicity and reduced PD-L1 expression in pancreatic cancer","volume":"12","author":"Principe","year":"2022","journal-title":"Front Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf430\/66341752\/oyaf430.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyaf430\/66341752\/oyaf430.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyaf430\/66341752\/oyaf430.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:36:38Z","timestamp":1770968198000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf430\/8419882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf430","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,1,10]]},"article-number":"oyaf430"}}